ClinConnect ClinConnect Logo
Search / Trial NCT06578962

Efficacy of a Cosmetic Shampoo RV3438G in Reccurent Squamous States

Launched by PIERRE FABRE DERMO COSMETIQUE · Aug 28, 2024

Trial Information

Current as of June 17, 2025

Completed

Keywords

Dermatitis, Seborrheic Scalp Adults Maintenance Of Effects

ClinConnect Summary

4 visits are performed: Visit 1: Inclusion (Day1) : start of the short intensive treatment phase (phase 1) Visit 2: Intermediate visit (Day15 ± 3 days, Week 2) : end of the short treatment intensive phase and start of the maintenance phase (phase 2) Visit 3: Intermediate visit (Day 43 ± 3 days, Week 6) : middle of the maintenance phase Visit 4: End-of-study visit (Day 71 ± 3 days, Week 10) : end of the maintenance phase

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Criteria related to the population:
  • - Subject aged between 18 and 60 years included
  • Criteria related to the disease:
  • Subject having a squamous state of the scalp :
  • clinically visible (Squire score ≥ 20),
  • with an intensity of the squamous state superior or equal to 2 on a scale from 0 to 3 on at - least 1 of the 4 scalp areas
  • recurrent (at least twice a year)
  • associated to erythema and pruritus: erythema scoring superior or equal to 1 on a scale from 0 to 3 on at least 1 scalp area desquamating of the 4 scalp areas pruritus scoring assessed by the subject superior or equal to 3 on a numerical scale from 0 to 10 (mean pruritus felt on the last 3 days)
  • Exclusion Criteria:
  • Criteria related to the diseases / skin condition:
  • Subject having frizzy hair
  • Subject with an alopecia having caused hair loss on the upper part of the scalp (Norwood Hamilton stage\> III, Ludwig ≥ I-4, alopecia aerata, alopecia totalis), Seborrheic dermatitis requiring medical treatment
  • Criteria related to treatments and/or products:
  • Systemic treatment with nonsteroidal anti-inflammatory, corticosteroid, antibiotic, antihistamine taken during 5 consecutive days within the 2 weeks before the inclusion or planned during the study and liable to interfere with the study assessments
  • Topical treatment or product applied on the scalp within 2 weeks before the inclusion or planned during the study that can be active on squamous states or that can limit the effectiveness of the study product: anti-inflammatory drugs, ketoconazole, anti-dandruff shampoo, anti-fungal, rinse with vinegar, essential oils ...
  • Any scalp dyeing, bleaching, perm, smoothing / straightening performed within 2 weeks before inclusion

About Pierre Fabre Dermo Cosmetique

Pierre Fabre Dermo-Cosmétique is a leading global player in the dermatology and dermo-cosmetics sectors, dedicated to developing innovative products that address a wide range of skin conditions and enhance skin health. Established as a subsidiary of Pierre Fabre Group, the company combines scientific expertise with a commitment to quality and efficacy, ensuring that its offerings are grounded in rigorous research and clinical validation. With a strong portfolio of brands, Pierre Fabre Dermo-Cosmétique focuses on patient-centric solutions, aiming to improve the quality of life for individuals with sensitive or compromised skin. The company's strategic approach to clinical trials underscores its dedication to advancing dermatological science and delivering reliable, safe products to healthcare professionals and consumers alike.

Locations

Paris, , France

Patients applied

0 patients applied

Trial Officials

Pascal REYGAGNE, Dr

Principal Investigator

Centre de santé SABOURAUD - Hôpital Saint Louis

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported